A219A5D7-C67B-4CF0-860A-78ADEB56A13D
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 0.9526938239159001
- age_years
- 49
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.643
- ANGIOGENESIS+0.624
- TNFA_SIGNALING_VIA_NFKB+0.587
- IL6_JAK_STAT3_SIGNALING+0.579
- INTERFERON_GAMMA_RESPONSE+0.546
- INFLAMMATORY_RESPONSE+0.528
- HYPOXIA+0.523
- INTERFERON_ALPHA_RESPONSE+0.520
- APOPTOSIS+0.505
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.485
Top 10 suppressed
- KRAS_SIGNALING_DN-0.375
- SPERMATOGENESIS-0.332
- PANCREAS_BETA_CELLS-0.292
- MITOTIC_SPINDLE-0.061
- WNT_BETA_CATENIN_SIGNALING-0.010
- HEDGEHOG_SIGNALING+0.017
- BILE_ACID_METABOLISM+0.042
- ESTROGEN_RESPONSE_EARLY+0.059
- MYOGENESIS+0.068
- ESTROGEN_RESPONSE_LATE+0.126
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 0E5EDC5A-5AD4-499E-8777-CA6B6F63307F | — | — | 0.983 |
| 2 | F9EB85A8-8E6D-44C0-8C59-50B1DB4E652B | — | — | 0.982 |
| 3 | 665044AD-F2DD-43C2-BCDE-982A8F5C5830 | — | — | 0.981 |
| 4 | 6727027F-4BAB-41ED-87F3-ECC7B1718ECF | — | — | 0.980 |
| 5 | F9A39954-57EB-4A3F-97A0-1801B08BBD53 | — | — | 0.979 |
| 6 | 25C4D537-0142-4DAA-874B-BC793336DE82 | — | — | 0.977 |
| 7 | 44B1F003-553A-4C8A-A6AE-44C49262081C | — | — | 0.976 |
| 8 | SRR934913 | — | — | 0.975 |
| 9 | 825AC0F8-4D16-4109-AA6A-4648934E3C35 | — | — | 0.975 |
| 10 | 3D3C3AAA-2C7A-43C6-8137-73A6E0896FAC | — | — | 0.973 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 45 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.643 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.624 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.587 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.579 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.546 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.528 | Idelalisib | — uncovered |
| HYPOXIA | 0.523 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.520 | Inavolisib | — uncovered |
| APOPTOSIS | 0.505 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.485 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.483 | Idelalisib | — uncovered |
| COAGULATION | 0.467 | Binimetinib | — uncovered |
| GLYCOLYSIS | 0.466 | Inavolisib | — uncovered |
| COMPLEMENT | 0.459 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.459 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.459 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.446 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.438 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.420 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.419 | Remibrutinib | — uncovered |